glp-1 receptor agonist with dpp-4 inhibitor combination not recommended do combine inhibitors agonists guidance What classes of diabetes GLP 1 Receptor Agonists and
Description
CagriSema combination weight loss The most relevant comparison for cagrilintide, however, is not cagrilintide alone

Mol Metab (2021) 46:101102

Both medications are preferred options for diabetic patients with or at risk for cardiovascular disease

In this trial, individuals who received Wegovy lost 6.2% of their initial body weight compared to those who received a placebo
doi: 10.1172/JCI140046 46 RobergeJNBrubakerPL
The results of the study supported this, showing that 15 mg of tirzepatide caused a decrease in pro-C3 by Week 26
